Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Oct;9(10):579-90.
doi: 10.1038/nrclinonc.2012.150. Epub 2012 Sep 4.

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

Jan J Cornelissen  1 , Alois Gratwohl, Richard F Schlenk, Jorge Sierra, Martin Bornhäuser, Gunnar Juliusson, Zdenek Råcil, Jacob M Rowe, Nigel Russell, Mohamad Mohty, Bob Löwenberg, Gerard Socié, Dietger Niederwieser, Gert J Ossenkoppele
Affiliations
Review

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

Jan J Cornelissen et al. Nat Rev Clin Oncol. 2012 Oct.

Abstract

Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual's risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Oncol. 2010 Feb 1;28(4):570-7 - PubMed
    1. N Engl J Med. 2010 Dec 16;363(25):2424-33 - PubMed
    1. Blood. 2003 Aug 15;102(4):1232-40 - PubMed
    1. Leukemia. 2009 Apr;23(4):635-40 - PubMed
    1. Blood. 2011 Feb 17;117(7):2137-45 - PubMed